Previous 10 | Next 10 |
home / stock / mdna:cc / mdna:cc news
Resverlogix Corp. (RVX:CA) is expected to report for Q1 2024 SNC-Lavalin Group Inc. (ATRL:CA) is expected to report $0.37 for Q3 2023 Cascadero Copper Corporation (CCD:CA) is expected to report for quarter end 2023-08-31 Pivotree Inc. (PVT:CA) is expected to report $-0.03 for Q3 2023 ...
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and a...
Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R ⍺ 2 targeted therapy that delivers ...
Oncolytics Biotech Inc. (ONC:CA) is expected to report $-0.1 for Q3 2023 Enbridge Inc. (ENB:CA) is expected to report $0.59 for Q3 2023 Magna International Inc. (MG:CA) is expected to report $1.86 for Q3 2023 Laramide Resources Ltd. (LAM:CA) is expected to report for Q2 2024 Ensig...
Medicenna Therapeutics Corp. (MDNA:CA) is expected to report $-0.06 for Q2 2024
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received ...
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 do...
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38 th Annu...
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphr...
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signalling MDNA223 demonstrated superior efficacy and extended survival in multiple immunologically “hot ...
News, Short Squeeze, Breakout and More Instantly...
Medicenna Therapeutics Corp. Company Name:
MDNA:CC Stock Symbol:
TSXC Market:
Medicenna Therapeutics Corp. Website:
Melcor Real Estate Investment Trust (MR.UN:CA) is expected to report for Q2 2024 Galleon Gold Corp. (GGO:CA) is expected to report for Q2 2024 Koryx Copper Inc. (KRY:CA) is expected to report for Q3 2024 Medicure Inc. (MPH:CA) is expected to report for Q2 2024 Pinetree Capital Ltd...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...